[Essai d'un dispositif non approuvé ou autorisé par la FDA américaine]
21 juillet 2026 mis à jour par: Elise Marino, The University of Texas Health Science Center at San Antonio
The researchers will study the KIOS app, a digital health tool made to help people recovering from opioid addiction take better care of themselves.
They want to see how the app works in real life and learn who benefits most from using it.
The study will also ask participants what they think about the app and how easy it is to use.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Description détaillée
Participation in the study will last 12 months. Participants will be asked to complete assessments at 33 timepoints over the 12-month trial. This will include 1 screening assessment, 24 weekly assessments, 6 monthly assessments, and 2 follow-up assessments. All study assessments will be completed remotely.
Staff at each site will identify potential participants being treated with buprenorphine for opioid use disorder at their respective site. Providers will introduce the study and if interested, the participant will complete a screening assessment conducted by trained study staff to determine eligibility for the study.
Participants who are eligible will be enrolled into the study and given access to the KIOS app.
The active phase will include the first 6 months during which time participants will use the app, complete monthly assessments, and complete a weekly craving assessment. The second 6 months in the study will include two follow-up assessments at 9 months and 12 months post study start. At the end of the 12 months, app access will be removed. The follow up assessments will include the monthly assessments that were completed during the active phase, as well as the craving assessment. All assessments will be sent to the participants' email address for them to complete on any device with internet access. At the conclusion of 12 months of study participation, focus groups will be conducted with 25 of the participants to gather information about their perspectives on the app and its usability and features.
Type d'étude
Interventionnel
Inscription (Estimé)
134
Phase
- N'est pas applicable
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Elise Marino, PhD
- Numéro de téléphone: (210) 567-5399
- E-mail: marinoe@uthscsa.edu
Sauvegarde des contacts de l'étude
- Nom: McKenna Garcia
- Numéro de téléphone: (210) 450-7371
- E-mail: garciam98@uthscsa.edu
Lieux d'étude
-
-
Texas
-
San Antonio, Texas, États-Unis, 78229
- University of Texas Health Science Center - Department of Psychiatry
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Non
La description
Inclusion Criteria:
- Male or female outpatients 18 years of age or older
- DSM-5 criteria for opioid use disorder
- Ability to access KIOS via smartphone or tablet
- Initiated buprenorphine treatment in the past 6 months
Exclusion Criteria:
- Unwilling or unable to comply with study requirements
- A psychiatric or medical condition interfering with ability to use the app
- Incarceration
- Suicide risk as determined by the treating medical clinician at the site
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Recherche sur les services de santé
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Treatment as usual and KIOS app
Participants will be set up onto their preferred device(s) with assistance from a research assistant.
KIOS will be accessible on all mobile devices as well as tablets.
Treatment as usual (TAU) will be administered to all participants.
|
A digital health therapeutic intended to help individuals in recovery from opioid use disorder better self-manage their condition.
KIOS offers individualized, evidence-based behavioral intervention strategies responsive to the patients' current clinical status outside the setting of the doctor's office or treatment facility.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Retention in treatment
Délai: Baseline to 1 year
|
The number of days from the start of the one-year intervention until the participant either leaves the trial or completes the trial.
|
Baseline to 1 year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Diagnostic Statistical Manual Version 5 (DSM-5)
Délai: Baseline to 12 months
|
DSM-5 criteria describe OUD as a pattern of opioid use leading to problems or distress
|
Baseline to 12 months
|
|
Opioid Craving Scale
Délai: Baseline to 12 months
|
A brief 3-item measure used to measure opioid craving.
The scale consists of 3 items rated on a visual analog scale from 0-10.
Items are as follows: 1) How much do you currently crave opiates?; 2) In the past week, please rate how strong your desire to use opiates has been when something in the environment has reminded you of opiates?; and 3) Please imagine yourself in the environment in which you previously used opiates.
If you were in this environment today and if it were the time of day that you typically used opiates, what is the likelihood that you would use opiates today.
The total scores range from 3-30 with a higher score indicating more opioid craving.
|
Baseline to 12 months
|
|
Patient Health Questionnaire-9 (PHQ-9)
Délai: Baseline to 12 months
|
A self-administered 9-item depression module that scores each of the 9 DSM-V (Diagnostic and Statistical Manual of Mental Disorders, 5th edition).
Items are score 0 to 3, providing a 0 to 27 severity score.
Scores of 5, 10, 15, and 20 represent cutoff points for mild, moderate, moderately severe, and severe depression, respectively.
|
Baseline to 12 months
|
|
Generalized Anxiety Disorder-7 (GAD-7)
Délai: Baseline to 12 months
|
The Generalized Anxiety Disorder-7 (GAD-7)13 measures anxiety with 7 items scored from 0 to 3, providing a 0 to 21 severity score.
Scores of 5, 10, and 15 represent cutoff points for mild, moderate, and severe anxiety, espectively.
|
Baseline to 12 months
|
|
Treatment Progress and Recovery (TEA)
Délai: 6 to 12 months
|
The TEA gauges progress in treatment and recovery within four domains established by prior research: substance use, health (physical or emotional), lifestyle (housing/living situation, family, employment, relationships), and community (obeying laws, responsible member of society).
For each area, the patient is asked to think about how much better things have become on a 10-point scale (1 = not better at all and 10 = very much better).
Scores range between 0-40, with a higher score indicating greater progress in treatment and recovery
|
6 to 12 months
|
|
System Usability Scale (SUS)
Délai: 6 months
|
The System Usability Scale (SUS)15 is a 10-item measure for assessing a system's usability on a 5-point Likert scale from strongly agree to strongly disagree.
Scores are converted to a 100-point scale.
A score above a 68 would be considered above average usability.
|
6 months
|
|
KIOS User Satisfaction Survey
Délai: 6 months
|
Participants complete a survey specific to KIOS regarding: (1) the content, appropriateness, and relevance of the advice; (2) enhancement of self-management skills; (3) selfawareness; and (4) overall satisfaction with health.
Survey items will be answered with level of agreement with a given statement recorded on a Likert-type 0 (Disagree) - 7 (Agree) scale.
|
6 months
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Les enquêteurs
- Chercheur principal: Elise Marino, PhD, The University of Texas Health Science Center at San Antonio
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
17 août 2026
Achèvement primaire (Estimé)
31 mai 2028
Achèvement de l'étude (Estimé)
30 juin 2028
Dates d'inscription aux études
Première soumission
15 janvier 2026
Première soumission répondant aux critères de contrôle qualité
15 janvier 2026
Première publication (Réel)
16 janvier 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
23 juillet 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
21 juillet 2026
Dernière vérification
1 juillet 2026
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- STUDY00002308
- 4R44DA059017-02 (Subvention/contrat des NIH des États-Unis)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Non
Étudie un produit d'appareil réglementé par la FDA américaine
Oui
produit fabriqué et exporté des États-Unis.
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .